Entera Bio adds ex-Gilead EVP Laura Hamill to board; Yonatan Malca exits after 16 years

Entera Bio Ltd.

Laura Hamill, 62, appointed Class I director effective December 1, 2026; also joins the audit and corporate governance/nomination committees.
Hamill was EVP Worldwide Commercial Operations at Gilead Sciences, leading ~2,500 employees and $22B in annual revenue; spent nearly two decades at Amgen.
She succeeds Yonatan Malca, who steps down December 1, 2026 after 16 years of service; company says departure is not due to any disagreement.
CEO Miranda Toledano cites Hamill's experience for late-stage execution and commercial preparedness for EB613 in osteoporosis and the oral peptide pipeline.
Hamill currently sits on boards of Jazz Pharmaceuticals (JAZZ), BB Biotech AG and Fate Therapeutics (FATE); compensation is standard non-employee director terms under the 2018 Equity Incentive Plan.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Yonatan Malca

director

ENTXW · Entera Bio Ltd.

Effective: 2026-12-01
Filed: October 6, 2026, 8:00 AM ET

On October 6, 2026, Yonatan Malca notified the Board that he would step down as a director, effective December 1, 2026.

Appointed

Laura Hamill

Class I director

ENTXW · Entera Bio Ltd.

Effective: 2026-12-01
Filed: October 6, 2026, 8:00 AM ET

On October 6, 2026, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), appointed Laura Hamill as a Class I director of the Company, effective December 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yonatan Malca departed as director at Entera Bio Ltd..

Action: step down
Role: director

Exact text from the filing

On October 6, 2026, Yonatan Malca notified the Board that he would step down as a director, effective December 1, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Hamill was appointed as Class I director at Entera Bio Ltd..

Action: appointed
Role: Class I director

Exact text from the filing

On October 6, 2026, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), appointed Laura Hamill as a Class I director of the Company, effective December 1, 2026.

View on SEC.gov

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-004720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.